Why we like Starbucks’ latest turnaround move - plus, two more wins for Eli Lilly

{
  "signal_id": "08715ec7-f7cc-021c-8ad9-9dac72526fc7",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-09-24T19:06:08+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/09/24/why-we-like-starbucks-latest-turnaround-move-plus-two-more-wins-for-eli-lilly.html",
    "title": "Why we like Starbucks’ latest turnaround move - plus, two more wins for Eli Lilly",
    "excerpt": "Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch - an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were mixed Thursday as Treasury yields surged and investors raised their expectations for another Federal Reserve rate hike. However, encouraging headlines around a potential deal between the U.S. and Iran to reopen the Strait of Hormuz helped the major averages bounce well off their morning lows. The S & P 500 and tech-heavy Nasdaq Composite both crossed into positive territory after being down as much as 0.5% and 0.8%, respectively. The 10-year Treasury yield climbed to around 5.15%, near levels last seen in 2007 , while the 30-year touched 5.458%, its highest since 2004 . Oil added to the pressure, with Brent crude rising as high as $108 a barrel. Fed funds futures now imply a 68.6% chance of another rate hike in October, up from roughly 55% a week ago, according to the CME FedWatch tool . We're also watching Thursday's meeting between President Donald Trump and Chinese President Xi Jinping for any developments around a potential aircraft order for Club holding Boeing , though we're not holding our breath. Starbucks announced it will close about 250 underperforming North American cafes , or roughly 1% of its footprint in the region, as CEO Brian Niccol continues his turnaround efforts . Starbucks...",
    "summary": "Eli Lilly is investing to broaden its pipeline through a research and licensing agreement with Chinese drugmaker InnoCare Pharma worth up to $3.35 billion.",
    "planning": true,
    "image_url": "https://image.cnbcfm.com/api/v1/image/108225357-1763036722348-gettyimages-2244585244-AFP_833H39L.jpeg?v=1763036813&w=1920&h=1080",
    "confidence": 0.9,
    "published_at": "2026-09-24T19:06:08Z",
    "article_sentence": "Lilly is also investing to broaden its pipeline through a research and licensing agreement with Chinese drugmaker InnoCare Pharma worth up to $3.35 billion.",
    "amount_normalized": 3350000000,
    "related_company_name": "InnoCare Pharma",
    "related_company_domain": "innocarepharma.com"
  }
}

curl https://signals.autobound.ai/v1/signals/08715ec7-f7cc-021c-8ad9-9dac72526fc7 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'